Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 6/20 | 0.53 |
| ▸ | TOP1 | P11387 | 1/20 | 0.38 |
| ▸ | CYCS | P99999 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2553046 | 0.98 | TERT (0.52) | TERTTOP1 | |
| SCHEMBL450416 | 0.98 | TERT (0.54) | TERTTOP1CYCS | |
| Hydrochloric Acid SCHEMBL2555721 | 0.97 | TERT (0.53) | TERTTOP1CYCS | |
| Hydrochloric Acid SCHEMBL2555716 | 0.95 | TERT (0.52) | TERTTOP1 | |
| Hydrochloric Acid SCHEMBL2553050 | 0.95 | TERT (0.51) | TERTTOP1CYCS | |
| SCHEMBL4552175 | 0.91 | TERT (0.58) | TERTTOP1CYCS | |
| SCHEMBL23631762 | 0.89 | TERT (0.45) | TERT | |
| SCHEMBL23631759 | 0.89 | TERT (0.45) | TERT | |
| SCHEMBL4263240 | 0.88 | TERT (0.46) | TERT | |
| SCHEMBL4271237 | 0.88 | TERT (0.46) | TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9999627-B2 | Methods of treating erectile dysfunction | BioMimetix, JV, LLC (US) | 2018-06-19 | — | — | US | disclosed |
| US-20160101115-A1 | METHODS OF TREATING ERECTILE DYSFUNCTION | NATIONAL JEWISH HEALTH | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101115-A1 | METHODS OF TREATING ERECTILE DYSFUNCTION | PDE3A, PDE3B, PDE2A | TERT 2665/4885TOP1 236/4885CYCS 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.